SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended (the
"Exchange Act")
Date of Report: May 31, 2000
ROCKY POINT PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
WASATCH PHARMACEUTICAL, INC.
(Former Name of registrant)
Nevada 33-55254-09 87-0434293
(State or other jurisdiction (Commission file (IRS Employer
of incorporation number) Identification Number)
50 West Broadway, Suite 1111
Salt Lake City, Utah 84101
(Address of Principal Executive offices) (Zip Code)
1466 Vintry
Salt Lake City, Utah 84121
(Former Address of Principal (Zip Code)
Executive offices)
Registrant's Telephone Number, including area code: (801) 363-1600
1
<PAGE>
Item 5. Other Events
On May 31, 2000 at a special shareholders' meeting, the Company's name was
changed from Wasatch Pharmaceutical, Inc. to Rocky Point Pharmaceuticals, Inc.
Neil E. Crabtree and Dr. Robert Morrow were elected as directors. Neil E.
Crabtree was appointed as President and Dr. Robert Morrow was appointed as
Secretary/Treasurer.
Mr. Crabtree and Dr. Morrow are now the only officers and directors after Mark
Timothy resigned as President and a Director.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ROCKY POINT PHARMACEUTICALS, INC.
Dated: June 22, 2000 By:
Neil E. Crabtree
President and Director
2
